Previous 10 | Next 10 |
2023-11-15 11:05:05 ET More on IceCure Medical IceCure Medical 9M GAAP EPS of -$0.26, revenue of $2M IceCure stock soars 85% in pre-market trading on positive study results Seeking Alpha’s Quant Rating on IceCure Medical Historical earnings data for Ic...
2023-11-15 08:04:11 ET More on IceCure Medical IceCure stock soars 85% in pre-market trading on positive study results IceCure Medical shares plunge 40% on FDA update Seeking Alpha’s Quant Rating on IceCure Medical Historical earnings data for IceCure ...
IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights PR Newswire ProSense® system and disposables sales continue upward trend compared to the equivalent prior year period...
IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense® in Early-Stage Breast Cancer PR Newswire Objective is to reopen file to address comments and find appropriate comparator group that is more representative of the...
The RMR Group Inc. (RMR) is expected to report $0.46 for Q4 2023 Indra Sistemas ADR (ISMAY) is expected to report for Q3 2023 Ceapro Inc. (CRPOF) is expected to report for Q2 2024 Tuya Inc. American Depositary Shares each representing one Class A (TUYA) is expected to report $-0.02 fo...
IceCure Medical Ltd. (ICCM) is expected to report $-0.09 for Q3 2023
IceCure Medical to Report Third Quarter 2023 Financial & Operational Results on November 15, 2023 IceCure Medical to Report Third Quarter 2023 Financial & Operational Results on November 15, 2023 PR Newswire CAESAREA, Israel , Nov. 8, 2023 /PRNewswire...
Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's ProSense® Cryoablation System PR Newswire Independent, non-sponsored studies by doctors using ProSense® to treat cancers of the breast, lung, kidney, and ...
2023-11-03 16:06:13 ET More on IceCure Medical IceCure stock soars 85% in pre-market trading on positive study results IceCure Medical shares plunge 40% on FDA update Seeking Alpha’s Quant Rating on IceCure Medical Historical earnings data for IceCure ...
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire CAESAREA, Israel , Nov. 3, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), a developer of the ProSense® System, a minimally-invasive...
News, Short Squeeze, Breakout and More Instantly...
99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society PR Newswire Demand for minimally invasive breast cancer treatment was ove...
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment fo...
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes PR Newswire CAESAREA, Israel , July 1, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medic...